Abstract:Background Clear cell renal cell carcinoma (ccRCC) is a malignant tumor with limited treatment options. A recent study confirmed the involvement of basement membrane (BM) genes in the progression of many cancers. Therefore, we studied the role and prognostic significance of BM genes in ccRCC. Methods Co-expression analysis of ccRCC-related information deposited in The Cancer Genome Atlas database and a BM geneset from a recent study was conducted. The differentially expressed BM genes were validated using quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Least absolute shrinkage and selection operator regression and univariate Cox regression analyses were performed to identify a BM gene signature with prognostic significance for ccRCC. Multivariate Cox regression, time-dependent receiver operating characteristic, Kaplan–Meier, and nomogram analyses were implemented to appraise the prognostic ability of the signature and the findings were further verified using a Gene Expression Omnibus dataset. Additionally, immune cell infiltration and and pathway enrichment analyses were performed using ImmuCellAI and Gene Set Enrichment Analysis (GSEA), respectively. Finally, the DSIGDB dataset was used to screen small-molecule therapeutic drugs that may be useful in treating ccRCC patients. Results We identified 108 BM genes exhibiting different expression levels compared to that in normal kidney tissues, among which 32 genes had prognostic values. The qRT-PCR analyses confirmed that the expression patterns of four of the ten selected genes were the same as the predicted ones. Additionally, we successfully established and validated a ccRCC patient prediction model based on 16 BM genes and observed that the model function is an independent predictor. GSEA revealed that differentially expressed BM genes mainly displayed significant enrichment of tumor and metabolic signaling cascades. The BM gene signature was also associated with immune cell infiltration and checkpoints. Eight small-molecule drugs may have therapeutic effects on ccRCC patients. Conclusion This study explored the function of BM genes in ccRCC for the first time. Reliable prognostic biomarkers that affect the survival of ccRCC patients were determined, and a BM gene-based prognostic model was established.

Loss of BRM expression is a frequently observed event in poorly differentiated clear cell renal cell carcinoma.

BRM/SMARCA2‐negative Clear Cell Renal Cell Carcinoma is Associated with a High Percentage of BRM Somatic Mutations, Deletions and Promoter Methylation

Coexistent Loss of Ini1 and Brg1 Expression in A Rhabdoid Renal Cell Carcinoma (rcc): Implications for A Possible Role of Swi/Snf Complex in the Pathogenesis of Rcc

Expression of BRG1 and BRM Proteins in Prostatic Cancer

Hypermethylation of BRM Promoter Plays Oncogenic Roles in Development of Clear Cell Renal Cell Carcinoma

SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature

Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma with PBRM1, SETD2, BAP1, or KDM5C Mutations

Analysis of PBRM 1 gene mutations in 53 Chinese patients with clear cell renal cell carcinoma

Inactivation of BRM/SMARCA2 Sensitizes Clear Cell Renal Cell Carcinoma to Histone Deacetylase Complex Inhibitors

BRG1 loss in MiaPaCa2 cells induces an altered cellular morphology and disruption in the organization of the actin cytoskeleton

Comprehensive Genomic Profiling in Chinese Patients with Clear Cell Renal Cell Carcinoma.

Comprehensive Analyses of PBRM1 in Multiple Cancer Types and Its Association with Clinical Response to Immunotherapy and Immune Infiltrates.

Abstract 1494: PBRM1-deficient PBAF complexes target de novo genomic loci to activate NF-κB pathway in clear cell renal cell carcinoma

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma

High Peritumoral Bmi-1 Expression is an Independent Prognosticator of Poor Prognosis in Renal Cell Carcinoma.

PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma

Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.

Expression of basement membrane genes and their prognostic significance in clear cell renal cell carcinoma patients

Abstract PR003: PBRM1-deficient PBAF complexes target aberrant genomic loci to activate NF-κB pathway in clear cell renal cell carcinoma

SMARCC1 Expression is Positively Correlated with Pathological Grade and Good Prognosis in Renal Cell Carcinoma

Evaluation of PD-L1 expression in PBRM1-altered clear cell renal cell carcinoma